AMS · XBRL financial data

American Shared Hospital Services financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AMS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	17,837	17,628	19,746	21,325	28,340	28,082
Cost of revenue	13,371	10,902	11,364	11,981	19,155	23,018
Gross profit	4,466	6,726	8,382	9,344	9,185	5,064
Selling, general and administrative	4,608	4,531	5,145	7,022	7,407	7,078
Operating income (loss)	(9,463)	1,351	2,431	270	(2,805)	(3,588)
Interest expense	1,057	739	806	1,112	1,499	1,574
Income tax expense (benefit)	(1,737)	269	963	431	(295)	(493)
Net income (loss)	(7,058)	194	1,328	610	2,186	(1,553)
Earnings per share, basic USD per share	(1.14)	0.03	0.21	0.10	0.34	(0.23)
Earnings per share, diluted USD per share	(1.14)	0.03	0.21	0.10	0.33	(0.23)
Weighted average shares, basic thousands of shares	6,182	6,044	6,297	6,358	6,497	6,616
Weighted average shares, diluted thousands of shares	6,182	6,059	6,303	6,393	6,703	6,616

Fiscal years (AMS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	3,961	8,145	12,335	13,690	11,025	3,462
Accounts receivable	4,303	4,211	3,801	4,343	11,610	10,521
Prepaid and other current assets	1,950	826	897	526	928	774
Total current assets	10,850	15,087	18,723	20,456	26,258	17,720
Property and equipment, net	30,418	—	—	—	—	—
Right-of-use asset	886	654	317	57	1,015	3,648
Goodwill	1,265	1,265	1,265	1,265	1,265	1,265
Total assets	43,653	45,430	43,956	48,162	60,197	55,479
Accounts payable	683	746	230	315	1,562	607
Current portion of long-term debt	1,157	1,081	1,262	2,084	2,841	17,294
Total current liabilities	12,380	5,891	5,175	10,779	10,405	23,444
Long-term debt	3,440	14,323	12,205	11,041	17,341	0
Lease liability, non-current	581	359	59	0	1,500	4,229
Total liabilities	—	21,191	18,331	21,883	30,170	27,788
Retained earnings	1,497	1,691	3,019	3,629	5,815	4,262
Total stockholders' equity	19,274	19,893	21,625	22,624	25,183	24,034
Total liabilities and equity	43,653	45,430	43,956	48,162	60,197	55,479
Common shares outstanding (cover page) thousands of shares	5,801	6,049	6,184	6,330	6,450	6,602

Fiscal years (AMS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,058)	194	1,328	610	2,186	(1,553)
Stock-based compensation	299	420	399	389	373	404
Depreciation and amortization	6,970	4,972	4,783	—	—	—
Net cash from operating activities	9,745	6,267	7,235	5,718	167	3,098
Purchases of property and equipment	455	1,674	388	6,273	7,938	7,634
Net cash from investing activities	(2,389)	(1,674)	(388)	(6,273)	(7,105)	(7,634)
Proceeds from long-term debt	0	13,897	0	1,750	9,860	0
Repayments of long-term debt	1,726	3,927	2,032	2,129	2,734	3,014
Net cash from financing activities	(4,810)	(655)	(2,657)	1,910	4,405	(3,027)
Net change in cash	2,546	3,938	4,190	1,355	(2,533)	(7,563)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
American Shared Hospital Services	6,511	8,430	2,236*	6.7M	—	Q2 FY26 10-QJun 30, 2026
CapForce	144	50,000	(618)*	12.4M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Ludwig Enterprises	18	not reported	(153)	167.2M	1.3 quarters	Q1 FY26 10-QMar 31, 2026
Biodesix	29,996	26,861	(1,562)*	10.6M	19.2 quarters	Q2 FY26 10-QJun 30, 2026
BioNexus Gene Lab	1,233	76	(422)*	2.9M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Aclarion	16,285	25	(2,657)*	2.9M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Advanced Biomed	386	year only	(583)*	1.7M	0.7 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.